General Info

Novavax is a biotechnology company focused on the research, development and commercialization of products utilizing its proprietary drug delivery solutions. The company's drug delivery technologies include Novasomes, Sterisomes and micellar nanoparticle technology, which is the basis for the development of the federally approved product, ESTRASORB. Novavax s vaccine technologies include its virus-like particle manufacturing technology, utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes and dendrimer technologies. In 2006, Kleiner Perkins Caufield & Byers acquired $12.5 million worth of Novavax s common stock, and Prospect Venture partners acquired $7.5 million worth of the company s common stock, which is in addition to the $5.5 million of previously accumulated equity it had purchased in the open market. Novavax is headquartered in Malvern, Pa.